GLP-1 Receptor Agonists and PrecisionLife Genetics in ME/CFS

This section covers literature at the intersection of ME/CFS genetics (PrecisionLife combinatorial analysis), GLP-1 receptor agonist biology, and the therapeutic potential of GLP-1 RAs for ME/CFS subgroups. The core finding from Gardner’s BRMEC15 presentation is that GLP-1 RA target pathways — synaptic and calcium signalling, glucose homeostasis, endothelial dysfunction — are enriched among the 250+ genes identified by PrecisionLife’s combinatorial analysis of ME/CFS. Protective genes for ME/CFS overlap with T2D, insulin-related signalling, and BMI pathways. Three potential subgroups for GLP-1 RA trials were proposed: autoimmune/inflammatory, cardiovascular, and energy metabolism.

1 Gardner 2026 — GLP-1 RAs: Hype, Hope and Hidden Dangers (BRMEC15)

Full Citation:: Gardner S. GLP-1 RAs: Hype, Hope and Hidden Dangers. Presented at: 15th Biomedical Research into ME Colloquium (BRMEC15); May 30, 2026; London, UK. (Gardner 2026) URL:: https://investinme.org/brmec15-stevegardner.shtml Published:: May 30, 2026 Study Design:: Conference presentation; combinatorial genetic analysis + clinical rationale Sample Size:: DecodeME + UK Biobank (n>20,000 cases); GLP-1 prediction cohort (n=4,600 Phase 1, scaling to 25,000 Phase 2) Key Findings::

- ME/CFS is highly polygenic and heterogeneous: different combinations of risk variants across patients
- GLP-1 RA target biological pathways (synaptic and calcium signalling, glucose homeostasis, endothelial dysfunction) are enriched among ME/CFS-associated genes
- Protective genes for ME/CFS overlap with T2D, insulin signalling, and BMI pathways
- Three subgroups proposed for GLP-1 RA trials: autoimmune/inflammatory, cardiovascular, energy metabolism
- AI-driven combinatorial analytics (PrecisionLife) enables prediction of GLP-1 efficacy and stratified patient selection
- Low-dose initiation recommended due to ME/CFS medication sensitivity

Conclusion:: GLP-1 receptor agonists warrant investigation in ME/CFS, with genetic stratification to identify responsive subgroups. The overlapping genetic architecture between ME/CFS protection and T2D/insulin/BMI pathways provides a mechanistic rationale. Limitations:: Conference presentation (not peer-reviewed); proprietary PrecisionLife platform; genetic findings require independent replication; GLP-1 RA efficacy in ME/CFS untested. Certainty:: 0.45

2 Ruhrländer et al. 2026 — Regulatory Cycles of Orexin and GLP-1 in Post-Viral Syndromes

Full Citation:: Ruhrländer J, Schieffer E, Schieffer B. Regulatory cycles of orexin and glucagon-like peptide-1 in post-viral syndromes. Endocrine Reviews. 2026;bnag009. Ruhrländer, Schieffer, and Schieffer (2026) DOI:: 10.1210/endrev/bnag009 PMID:: 42037238 Published:: April 27, 2026 Study Design:: Narrative review Sample Size:: N/A (review article) Key Findings::

- Orexin and GLP-1 form reciprocal regulatory cycles disrupted in post-viral syndromes including ME/CFS
- Orexin deficiency (hypoarousal) and GLP-1 dysregulation may create self-reinforcing metabolic and autonomic dysfunction
- Post-viral ME/CFS shares orexin-GLP-1 disruption features with PASC
- Identifies orexin-GLP-1 axis as potential therapeutic target

Conclusion:: Reciprocal orexin-GLP-1 dysregulation may drive core symptoms in post-viral syndromes; GLP-1 receptor modulation represents a candidate therapeutic strategy. Limitations:: Narrative review (no systematic search); ME/CFS-specific data limited; hypothesis-generating rather than confirmatory. Certainty:: 0.55

3 Athauda et al. 2026 — The Promise of GLP-1 Receptor Agonists for Neurodegenerative Diseases

Full Citation:: Athauda D, Greig NH, Meissner WG, Foltynie T, Gandhi S. The promise of GLP-1 receptor agonists for neurodegenerative diseases. Journal of Clinical Investigation. 2026;136(4):e194745. (Athauda et al. 2026) DOI:: 10.1172/JCI194745 PMID:: 41697753 Study Design:: Authoritative review Sample Size:: N/A (comprehensive literature review) Key Findings::

- GLP-1 RAs demonstrate neuroprotective effects across diverse neurodegenerative conditions
- Mechanisms include: reduced protein aggregation, enhanced autophagy, improved mitochondrial function, suppression of neuroinflammation, preservation of synaptic integrity
- Epidemiological analyses suggest reduced incidence of dementia, Parkinson's disease, and MS among GLP-1 RA users
- Phase II trials in Parkinson's and Alzheimer's show encouraging signals

Conclusion:: GLP-1 RAs represent a promising therapeutic strategy for neurodegenerative diseases, with converging preclinical and clinical evidence supporting disease-modifying potential. Limitations:: Review; no primary ME/CFS data; most clinical evidence from neurodegenerative populations, not post-viral fatigue. Certainty:: 0.80

4 Cukierman-Yaffe et al. 2020 — Dulaglutide and Cognitive Impairment (REWIND Trial)

Full Citation:: Cukierman-Yaffe T, Gerstein HC, Colhoun HM, Diaz R, García-Pérez LE, et al. Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial. Lancet Neurology. 2020;19(7):582-590. (Cukierman-Yaffe et al. 2020) DOI:: 10.1016/S1474-4422(20)30173-3 PMID:: 32562683 Study Design:: Exploratory analysis of randomised controlled trial (REWIND) Sample Size:: n=9,901; median 5.4 years follow-up Key Findings::

- Dulaglutide associated with reduced risk of cognitive impairment (HR 0.86, 95% CI 0.76-0.98)
- Consistent effect across multiple cognitive domains
- Benefit independent of glycaemic control — suggests direct neuroprotective effect
- Largest and longest GLP-1 RA cognitive outcome study to date

Conclusion:: GLP-1 receptor agonism may reduce cognitive decline in T2D; exploratory finding supports neuroprotective hypothesis. Limitations:: Exploratory (not primary endpoint); T2D population only (not ME/CFS); effect modest; mechanism unclear. Certainty:: 0.78

5 Ren et al. 2025 — GLP-1 RAs Reduce Circulating Inflammatory Markers: Meta-Analysis

Full Citation:: Ren Y, Chen Y, Zheng W, Kong W, Liao Y. The effect of GLP-1 receptor agonists on circulating inflammatory markers in type 2 diabetes patients: a systematic review and meta-analysis. Diabetes, Obesity and Metabolism. 2025;doi:10.1111/dom.16366. (Ren et al. 2025) DOI:: 10.1111/dom.16366 PMID:: 40230207 Study Design:: Systematic review and meta-analysis of RCTs Sample Size:: Multiple RCTs (meta-analysis) Key Findings::

- GLP-1 RAs significantly reduce circulating CRP, TNF-alpha, and IL-6 in T2D patients
- Anti-inflammatory effect is independent of glycaemic improvement
- Effect magnitude moderate but consistent across studies
- Supports anti-inflammatory mechanism as class effect of GLP-1 RAs

Conclusion:: GLP-1 RAs exert clinically meaningful anti-inflammatory effects in addition to metabolic benefits, supporting potential utility in inflammatory conditions. Limitations:: T2D population only; ME/CFS data absent; meta-analysis heterogeneity; publication bias not excluded. Certainty:: 0.72

6 Deng et al. 2025 — GLP-1 RAs in Immune Cell Biology and Autoimmune Diseases

Full Citation:: Deng S, Chen Z, Shi Y. Roles of glucagon-like peptide 1 receptor agonists in immune cell biology and autoimmune/autoinflammatory diseases. Cell & Bioscience. 2025;15:89. (Deng, Chen, and Shi 2025) DOI:: 10.1186/s13578-025-01486-8 PMID:: 41074143 Study Design:: Comprehensive review Sample Size:: N/A (review) Key Findings::

- GLP-1 RAs modulate T cell, macrophage, and dendritic cell function
- Reduce pro-inflammatory cytokine production from immune cells
- Promote regulatory T cell differentiation
- Show benefit in preclinical models of autoimmune disease

Conclusion:: GLP-1 RAs have broad immunomodulatory effects beyond metabolic action, providing mechanistic rationale for use in autoimmune and inflammatory conditions. Limitations:: Review; most evidence from preclinical models; autoimmune clinical trial data still emerging. Certainty:: 0.60

7 Bilgin et al. 2025 — GLP-1 RAs in Rheumatology: Scoping Review

Full Citation:: Bilgin E, Venerito V, Bogdanos DP. Glucagon-Like Peptide-1 (GLP-1) receptor agonists in rheumatology: a review of current evidence and future directions. Autoimmunity Reviews. 2025;103864. (Bilgin, Venerito, and Bogdanos 2025) DOI:: 10.1016/j.autrev.2025.103864 PMID:: 40617296 Study Design:: Scoping review (PRISMA-ScR) Sample Size:: 52 studies and 7 clinical trials Key Findings::

- GLP-1 RAs show anti-inflammatory effects in inflammatory arthritis, osteoarthritis, and systemic autoimmune diseases
- Reductions in disease activity scores and inflammatory biomarkers reported
- GLP-1 RA benefits may be independent of weight loss
- Evidence strongest for rheumatoid arthritis and psoriatic arthritis

Conclusion:: Emerging evidence supports GLP-1 RA repurposing for rheumatic and autoimmune diseases; controlled trials needed. Limitations:: Scoping review (evidence mapping, not formal synthesis); heterogeneity in study designs; most studies observational. Certainty:: 0.65

8 Spezani & Mandarim-de-Lacerda 2026 — GLP-1 RAs in Metabolic Dysfunction and Neuroinflammation

Full Citation:: Spezani R, Mandarim-de-Lacerda CA. Beyond diabetes and obesity: GLP-1 receptor agonists in disrupting the vicious cycle of metabolic dysfunction and neuroinflammation. Diabetes, Obesity and Metabolism. 2026;doi:10.1111/dom.70400. (Spezani and Mandarim-de-Lacerda 2026) DOI:: 10.1111/dom.70400 PMID:: 41417476 Study Design:: Narrative review Sample Size:: N/A (review) Key Findings::

- GLP-1 RAs disrupt the positive feedback cycle between metabolic dysfunction and neuroinflammation
- Microglial phenotype switching (M1→M2) mediated by GLP-1 receptor signalling
- Improved mitochondrial function in neurons and glia
- Restoration of insulin/IGF-1 signalling in the CNS

Conclusion:: GLP-1 RAs target both metabolic and neuroinflammatory components of neurodegenerative disease, suggesting utility in conditions where both are dysregulated. Limitations:: Narrative review; no systematic methodology; ME/CFS not discussed specifically. Certainty:: 0.55

9 Forny Germano et al. 2024 — Negative Result: Semaglutide and Tirzepatide in AD Mice

Full Citation:: Forny Germano L, Koehler JA, Baggio LL, Cui F, Wong CK, et al. The GLP-1 medicines semaglutide and tirzepatide do not alter disease-related pathology, behaviour or cognitive function in 5XFAD and APP/PS1 mice. Molecular Metabolism. 2024;89:102019. (Forny Germano et al. 2024) DOI:: 10.1016/j.molmet.2024.102019 PMID:: 39216535 Study Design:: Preclinical study in two transgenic AD mouse models Sample Size:: Two mouse models (5XFAD, APP/PS1) Key Findings::

- Semaglutide and tirzepatide showed no effect on amyloid pathology, behaviour, or cognition
- Negative result contrasts with previous positive findings for other GLP-1 RAs (e.g., liraglutide)
- Possible compound-specific or model-specific effects
- Cautions against assuming class-wide neuroprotection across all GLP-1 RAs

Conclusion:: Not all GLP-1 RAs show neuroprotective effects; compound selection matters for CNS indication development. Limitations:: Preclinical (mouse models); negative result may reflect model limitations or dose/route issues; single study. Certainty:: 0.70

10 Blitshteyn et al. 2026 — Semaglutide Improves POTS: Case Report

Full Citation:: Blitshteyn S, Suresh S, Lorenzi LM. Significant improvement of postural orthostatic tachycardia syndrome (POTS) with semaglutide: a case report. Clinical Autonomic Research. 2026;doi:10.1007/s10286-026-01197-1. (Blitshteyn, Suresh, and Lorenzi 2026) DOI:: 10.1007/s10286-026-01197-1 PMID:: 41739421 Study Design:: Single case report Sample Size:: n=1 Key Findings::

- Patient with POTS showed significant symptom improvement on semaglutide
- Improvement in heart rate, orthostatic tolerance, and quality of life
- Relevant to ME/CFS dysautonomia subgroup

Conclusion:: Semaglutide may benefit POTS-associated dysautonomia, warranting further investigation. Limitations:: Single case; no control; cannot distinguish direct effect from weight-loss-mediated improvement; ME/CFS not studied. Certainty:: 0.30

11 Afrin et al. 2025 — GLP-1 RAs in Mast Cell Activation Syndrome

Full Citation:: Afrin LB, Weinstock LB, Dempsey TT, Aschenbrenner K, Blitshteyn S. Utility of glucagon-like-peptide-1-receptor agonists in mast cell activation syndrome. American Journal of the Medical Sciences. 2025;doi:10.1016/j.amjms.2025.07.006. (Afrin et al. 2025) DOI:: 10.1016/j.amjms.2025.07.006 PMID:: 40675372 Study Design:: Case series/review Sample Size:: Small clinical series Key Findings::

- GLP-1 RAs may benefit mast cell activation syndrome (MCAS), which frequently co-occurs with ME/CFS
- MCAS presents with chronic multisystem inflammatory and allergic phenotypes
- GLP-1 RA anti-inflammatory effects may modulate mast cell activity
- Supports autoimmune/inflammatory subgroup for GLP-1 RA trials in ME/CFS

Conclusion:: GLP-1 RAs warrant investigation in MCAS and MCAS-overlap conditions including ME/CFS. Limitations:: Very early evidence; no controlled trials; small sample; Am J Med Sci (moderate journal). Certainty:: 0.35

12 Mehdi et al. 2023 — GLP-1: A Multi-Faceted Anti-Inflammatory Agent

Full Citation:: Mehdi SF, Pusapati S, Anwar MS, Lohana D, Kumar P. Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent. Frontiers in Immunology. 2023;14:1148209. (Mehdi et al. 2023) DOI:: 10.3389/fimmu.2023.1148209 PMID:: 37266425 Study Design:: Comprehensive review Sample Size:: N/A (review) Key Findings::

- GLP-1 has broad anti-inflammatory properties independent of glycaemic effects
- Modulates NF-kB and MAPK signalling pathways in immune cells
- Reduces pro-inflammatory cytokines (TNF-alpha, IL-6, IL-1beta) across organ systems
- GLP-1 levels correlate with disease severity in inflammatory conditions

Conclusion:: GLP-1 functions as an endogenous anti-inflammatory peptide; GLP-1 RAs harness this property for therapeutic benefit. Limitations:: Review; Frontiers journal; no ME/CFS-specific data; mechanism-to-symptom extrapolation required. Certainty:: 0.65

13 Reich & Hölscher 2022 — GLP-1 Neuroprotection in Alzheimer’s and Parkinson’s

Full Citation:: Reich N, Hölscher C. The neuroprotective effects of glucagon-like peptide 1 in Alzheimer’s and Parkinson’s disease: an in-depth review. Frontiers in Neuroscience. 2022;16:970925. (Reich and Hölscher 2022) DOI:: 10.3389/fnins.2022.970925 PMID:: 36117625 Study Design:: In-depth review Sample Size:: N/A (review) Key Findings::

- GLP-1 mimetics show neuroprotective effects in preclinical AD and PD models
- Phase II clinical trials in PD (exenatide) show promising disease-modifying signals
- GLP-1 RAs enhance synaptic plasticity, neurogenesis, and mitochondrial function
- Type 2 diabetes is a shared risk factor; GLP-1 RAs target common mechanisms

Conclusion:: GLP-1 RAs are among the most promising neuroprotective drug candidates for AD and PD. Limitations:: Review; clinical trial data primarily from PD; no ME/CFS-specific neuroprotection data. Certainty:: 0.60

14 Vear et al. 2025 — Incretin-Based Therapeutics for Neurodegenerative Diseases

Full Citation:: Vear A, Heneka MT, Clemmensen C. Incretin-based therapeutics for the treatment of neurodegenerative diseases. Nature Metabolism. 2025;7(4):706-722. (Vear, Heneka, and Clemmensen 2025) DOI:: 10.1038/s42255-025-01263-4 PMID:: 40211045 Study Design:: Authoritative review (Nature Metabolism) Sample Size:: N/A (comprehensive review) Key Findings::

- Dual GLP-1/GIP receptor agonists (e.g., tirzepatide) show enhanced neuroprotective effects
- Incretin-based therapies improve mitochondrial function, autophagy, and reduce neuroinflammation
- Blood-brain barrier penetration varies across incretin compounds
- Clinical trials expanding from diabetes to neurodegenerative indications

Conclusion:: Incretin-based therapies represent a promising therapeutic strategy for neurodegenerative diseases, with dual agonists potentially offering enhanced benefit. Limitations:: Review; clinical data primarily from diabetes and neurodegeneration; no ME/CFS-specific evidence. Certainty:: 0.75

15 Taylor et al. 2023 — Genetic Risk Factors for Long COVID and Commonalities with ME/CFS

Full Citation:: Taylor K, Pearson M, Das S, Sardell J, Chocian K, Gardner S. Genetic risk factors for severe and fatigue dominant long COVID and commonalities with ME/CFS identified by combinatorial analysis. Journal of Translational Medicine. 2023;21:756. (Taylor et al. 2023) DOI:: 10.1186/s12967-023-04588-4 PMID:: 37915075 Study Design:: Case-control genetic association study; combinatorial analysis Sample Size:: Long COVID cohort (PrecisionLife analysis) Key Findings::

- Genetic risk factors for severe and fatigue-dominant long COVID identified using combinatorial analysis
- Significant genetic overlap between long COVID and ME/CFS
- Distinct genetic architecture for long COVID subtypes (fatigue-dominant vs respiratory)
- Shared pathways include synaptic signalling and immune regulation

Conclusion:: Long COVID and ME/CFS share genetic risk architecture, supporting a common biological basis for post-viral fatigue syndromes. Limitations:: Single cohort; proprietary analytical platform; replication needed in independent cohorts. Certainty:: 0.60

16 Knudsen et al. 2011 — Media Portrayal of CFS

Full Citation:: Knudsen AK, Omenås AN, Harvey SB, Løvvik CM, Lervik LV, Mykletun A. Chronic fatigue syndrome in the media: a content analysis of newspaper articles. JRSM Short Reports. 2011;2(5):42. (Knudsen et al. 2011) DOI:: 10.1258/shorts.2011.011016 PMID:: 21637403 Study Design:: Content analysis of newspaper articles Sample Size:: 280 articles (UK and Norwegian newspapers) Key Findings::

- 70% of articles emphasized psychological causes or controversy
- Biological/medical framing was rare
- Headlines disproportionately used sceptical or dismissive language
- Media contributes to stigmatization through psychiatric characterisation

Conclusion:: Media representation of CFS emphasizes psychiatric framing and controversy, likely contributing to public stigma. Limitations:: Newspapers only (no broadcast/social media); UK and Norway only; dated (2011). Certainty:: 0.70

17 Ware 1999 — Social Course of Chronic Illness: CFS Model

Full Citation:: Ware NC. Toward a model of social course in chronic illness: the example of chronic fatigue syndrome. Culture, Medicine and Psychiatry. 1999;23(3):303–331. (Ware 1999) DOI:: 10.1023/A:1005577823045 PMID:: 10572737 Study Design:: Ethnographic study; narrative analysis Sample Size:: n=50 Key Findings::

- Disputed diagnosis leads to social marginalization
- Identity disruption from contested illness status
- Delegitimization by physicians, family, and broader society
- Proposes "social course" as parallel to clinical course in chronic illness

Conclusion:: The social course of CFS is characterized by progressive delegitimization that compounds clinical burden. Limitations:: Single ethnographic study; limited generalizability; dated (1999); not replicated with current diagnostic criteria. Certainty:: 0.60

18 Jason et al. 2002 — Illness Name and Stigma

Full Citation:: Jason LA, Taylor RR, Plioplys S, Stepanek Z, Shlaes J. Evaluating attributions for an illness based upon the name: chronic fatigue syndrome, myalgic encephalopathy and Florence Nightingale disease. American Journal of Community Psychology. 2002;30(1):133–148. (Jason et al. 2002) DOI:: 10.1023/A:1014328319297 PMID:: 11928774 Study Design:: Experimental vignette study Sample Size:: n=143 Key Findings::

- "Chronic fatigue syndrome" generates more negative attributions than "myalgic encephalopathy"
- "Florence Nightingale disease" generates the least negative attributions
- Name directly influences perceived seriousness and organicity

Conclusion:: The illness name itself is a vector of stigma; “myalgic encephalopathy” reduces negative attributions compared to “chronic fatigue syndrome.” Limitations:: Vignette methodology (hypothetical scenarios); student sample; dated (2002). Certainty:: 0.60

19 Johnson et al. 2022 — Suicide Risk Factors and Stigma in CFS

Full Citation:: Johnson ML, Cotler J, Terman JM, Jason LA. Risk factors for suicide in chronic fatigue syndrome. Death Studies. 2022;46(3):738–744. (Johnson et al. 2022) DOI:: 10.1080/07481187.2020.1776789 PMID:: 32527207 Study Design:: Cross-sectional survey; logistic regression Sample Size:: n=495 Key Findings::

- Perceived stigma and illness delegitimization associated with suicidal ideation after controlling for depression
- Prior suicide attempts more frequent in ME/CFS vs general population
- Stigma from healthcare providers specifically associated with worse outcomes

Conclusion:: Stigma and delegitimization are independent risk factors for suicide in ME/CFS, meriting clinical attention. Limitations:: Cross-sectional; online convenience sample; self-report measures. Certainty:: 0.68

References

Afrin, Lawrence B., Leonard B. Weinstock, Tania T. Dempsey, Katja Aschenbrenner, and Svetlana Blitshteyn. 2025. “Utility of Glucagon-Like-Peptide-1-Receptor Agonists in Mast Cell Activation Syndrome.” American Journal of the Medical Sciences. https://doi.org/10.1016/j.amjms.2025.07.006.

Athauda, Dilan, Nigel H. Greig, Wassilios G. Meissner, Thomas Foltynie, and Sonia Gandhi. 2026. “The Promise of GLP-1 Receptor Agonists for Neurodegenerative Diseases.” Journal of Clinical Investigation 136 (4): e194745. https://doi.org/10.1172/JCI194745.

Bilgin, Emre, Vincenzo Venerito, and Dimitrios P. Bogdanos. 2025. “Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Rheumatology: A Review of Current Evidence and Future Directions.” Autoimmunity Reviews, 103864. https://doi.org/10.1016/j.autrev.2025.103864.

Blitshteyn, Svetlana, Sanjana Suresh, and Lucia M. Lorenzi. 2026. “Significant Improvement of Postural Orthostatic Tachycardia Syndrome (POTS) with Semaglutide: A Case Report.” Clinical Autonomic Research. https://doi.org/10.1007/s10286-026-01197-1.

Cukierman-Yaffe, Tali, Hertzel C. Gerstein, Helen M. Colhoun, Rafael Diaz, Luis-Emilio García-Pérez, et al. 2020. “Effect of Dulaglutide on Cognitive Impairment in Type 2 Diabetes: An Exploratory Analysis of the REWIND Trial.” Lancet Neurology 19 (7): 582–90. https://doi.org/10.1016/S1474-4422(20)30173-3.

Deng, Sihui, Zeyu Chen, and Yuling Shi. 2025. “Roles of Glucagon-Like Peptide 1 Receptor Agonists in Immune Cell Biology and Autoimmune/Autoinflammatory Diseases.” Cell & Bioscience 15: 89. https://doi.org/10.1186/s13578-025-01486-8.

Forny Germano, Leticia, Jacqueline A. Koehler, Laurie L. Baggio, Fiona Cui, Chi Kin Wong, et al. 2024. “The GLP-1 Medicines Semaglutide and Tirzepatide Do Not Alter Disease-Related Pathology, Behaviour or Cognitive Function in 5XFAD and APP/PS1 Mice.” Molecular Metabolism 89: 102019. https://doi.org/10.1016/j.molmet.2024.102019.

Gardner, Steve. 2026. “GLP-1 RAs: Hype, Hope and Hidden Dangers.” https://investinme.org/brmec15-stevegardner.shtml.

Jason, Leonard A, Renee R Taylor, Sigita Plioplys, Zuzana Stepanek, and Jennifer Shlaes. 2002. “Evaluating Attributions for an Illness Based Upon the Name: Chronic Fatigue Syndrome, Myalgic Encephalopathy and Florence Nightingale Disease.” American Journal of Community Psychology 30 (1): 133–48. https://doi.org/10.1023/A:1014328319297.

Johnson, Madeleine L, Joseph Cotler, Julia M Terman, and Leonard A Jason. 2022. “Risk Factors for Suicide in Chronic Fatigue Syndrome.” Death Studies 46 (3): 738–44. https://doi.org/10.1080/07481187.2020.1776789.

Knudsen, Ann Kristin, Anne-Nina Omenås, Samuel B Harvey, Camilla M Løvvik, Linn V Lervik, and Arnstein Mykletun. 2011. “Chronic Fatigue Syndrome in the Media: A Content Analysis of Newspaper Articles.” JRSM Short Reports 2 (5): 42. https://doi.org/10.1258/shorts.2011.011016.

Mehdi, Syed Faizan, Suma Pusapati, Muhammad Saad Anwar, Durga Lohana, and Parkash Kumar. 2023. “Glucagon-Like Peptide-1: A Multi-Faceted Anti-Inflammatory Agent.” Frontiers in Immunology 14: 1148209. https://doi.org/10.3389/fimmu.2023.1148209.

Reich, Niklas, and Christian Hölscher. 2022. “The Neuroprotective Effects of Glucagon-Like Peptide 1 in Alzheimer’s and Parkinson’s Disease: An in-Depth Review.” Frontiers in Neuroscience 16: 970925. https://doi.org/10.3389/fnins.2022.970925.

Ren, Yifan, Yuzhang Chen, Wenbin Zheng, Wen Kong, and Yunfei Liao. 2025. “The Effect of GLP-1 Receptor Agonists on Circulating Inflammatory Markers in Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis.” Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.16366.

Ruhrländer, Jana, Elisabeth Schieffer, and Bernhard Schieffer. 2026. “Regulatory Cycles of Orexin and Glucagon-Like Peptide-1 in Post-Viral Syndromes.” Endocrine Reviews, bnag009. https://doi.org/10.1210/endrev/bnag009.

Spezani, Renata, and Carlos A. Mandarim-de-Lacerda. 2026. “Beyond Diabetes and Obesity: GLP-1 Receptor Agonists in Disrupting the Vicious Cycle of Metabolic Dysfunction and Neuroinflammation.” Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70400.

Taylor, Krystyna, Matthew Pearson, Sayoni Das, Jason Sardell, Karolina Chocian, and Steve Gardner. 2023. “Genetic Risk Factors for Severe and Fatigue Dominant Long COVID and Commonalities with ME/CFS Identified by Combinatorial Analysis.” Journal of Translational Medicine 21: 756. https://doi.org/10.1186/s12967-023-04588-4.

Vear, Anika, Michael T. Heneka, and Christoffer Clemmensen. 2025. “Incretin-Based Therapeutics for the Treatment of Neurodegenerative Diseases.” Nature Metabolism 7 (4): 706–22. https://doi.org/10.1038/s42255-025-01263-4.

Ware, Norma C. 1999. “Toward a Model of Social Course in Chronic Illness: The Example of Chronic Fatigue Syndrome.” Culture, Medicine and Psychiatry 23 (3): 303–31. https://doi.org/10.1023/A:1005577823045.